Raymond James Downgrades Jounce Therapeutics (JNCE) to Market Perform, 'It’s over for our constructive thesis on JTX-8064'
Tweet Send to a Friend
(Updated - February 23, 2023 3:49 AM EST)
Raymond James analyst Steven Seedhouse downgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Steven Seedhouse downgraded Jounce Therapeutics (NASDAQ: JNCE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
